The role of IRES trans-acting factors in carcinogenesis

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1849, Issue 7, 2015, Pages 887-897

  Faye, Mame Daro ^a,b   Holcik, Martin ^a,b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Apoptosis; Cancer; Cellular stress; IRES; RNA binding protein; Selective translation

Indexed keywords

BINDING PROTEIN; DEATH ASSOCIATED PROTEIN 5; INTERLEUKIN ENHANCER BINDING FACTOR 2; INTERLEUKIN ENHANCER BINDING FACTOR 3; IRES TRANS ACTING FACTOR; MESSENGER RNA; MICRORNA; PROTEIN; PROTEIN P53; RNA BINDING PROTEIN; SOMATOMEDIN B; TRANS ACTING FACTOR; UNCLASSIFIED DRUG; RNA; TUMOR PROTEIN;

APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; CYTOKINESIS; DNA DAMAGE; EPITHELIAL MESENCHYMAL TRANSITION; HOMEOSTASIS; HYPOXIA; INTERNAL RIBOSOME ENTRY SITE; METASTASIS; MITOSIS; NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA METABOLISM; TRANSLATION INITIATION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PROTEIN SYNTHESIS;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN BIOSYNTHESIS; RNA, NEOPLASM; RNA-BINDING PROTEINS;

EID: 84930818256     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2014.09.012     Document Type: Review

References (139)

1. Rudra D., Warner J.R. What better measure than ribosome synthesis?. Genes Dev. 2004, 18:2431-2436.
2. Holcik M., Sonenberg N. Translational control in stress and apoptosis. Nat. Rev. Mol. Cell Biol. 2005, 6:318-327.
3. Zetterberg A., Larsson O., Wiman K.G. What is the restriction point?. Curr. Opin. Cell Biol. 1995, 7:835-842.
4. Clemens M.J., Bushell M., Jeffrey I.W., Pain V.M., Morley S.J. Translation initiation factor modifications and the regulation of protein synthesis in apoptotic cells. Cell Death Differ. 2000, 7:603-615.
5. Bushell M., Stoneley M., Sarnow P., Willis A.E. Translation inhibition during the induction of apoptosis: RNA or protein degradation?. Biochem. Soc. Trans. 2004, 32:606-610.
6. Silvera D., Formenti S.C., Schneider R.J. Translational control in cancer. Nat. Rev. Cancer 2010, 10:254-266.
7. Ruggero D. Translational control in cancer etiology. Cold Spring Harb. Perspect. Biol. 2013, 5.
8. Liwak U., Faye M.D., Holcik M. Translation control in apoptosis. Exp. Oncol. 2012, 34:218-230.
9. Donze O., Jagus R., Koromilas A.E., Hershey J.W., Sonenberg N. Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells. EMBO J. 1995, 14:3828-3834.
10. Shimada A., Shiota G., Miyata H., Kamahora T., Kawasaki H., Shiraki K., Hino S., Terada T. Aberrant expression of double-stranded RNA-dependent protein kinase in hepatocytes of chronic hepatitis and differentiated hepatocellular carcinoma. Cancer Res. 1998, 58:4434-4438.
11. Kim S.H., Forman A.P., Mathews M.B., Gunnery S. Human breast cancer cells contain elevated levels and activity of the protein kinase, PKR. Oncogene 2000, 19:3086-3094.
12. Graff J.R., Konicek B.W., Carter J.H., Marcusson E.G. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res. 2008, 68:631-634.
13. Coleman L.J., Peter M.B., Teall T.J., Brannan R.A., Hanby A.M., Honarpisheh H., Shaaban A.M., Smith L., Speirs V., Verghese E.T., McElwaine J.N., Hughes T.A. Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br. J. Cancer 2009, 100:1393-1399.
14. Koromilas A.E., Lazaris-Karatzas A., Sonenberg N. mRNAs containing extensive secondary structure in their 5' non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E. EMBO J. 1992, 11:4153-4158.
15. Johannes G., Carter M.S., Eisen M.B., Brown P.O., Sarnow P. Identification of eukaryotic mRNAs that are translated at reduced cap binding complex eIF4F concentrations using a cDNA microarray. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:13118-13123.
16. Spriggs K.A., Stoneley M., Bushell M., Willis A.E. Re-programming of translation following cell stress allows IRES-mediated translation to predominate. Biol. Cell. 2008, 100:27-38.
17. Spriggs K.A., Bushell M., Willis A.E. Translational regulation of gene expression during conditions of cell stress. Mol. Cell 2010, 40:228-237.
18. Holcik M., Sonenberg N., Korneluk R.G. Internal ribosome initiation of translation and the control of cell death. Trends Genet. 2000, 16:469-473.
19. Bushell M., Stoneley M., Kong Y.W., Hamilton T.L., Spriggs K.A., Dobbyn H.C., Qin X., Sarnow P., Willis A.E. Polypyrimidine tract binding protein regulates IRES-mediated gene expression during apoptosis. Mol. Cell 2006, 23:401-412.
20. Komar A.A., Mazumder B., Merrick W.C. A new framework for understanding IRES-mediated translation. Gene 2012, 502:75-86.
21. Spriggs K.A., Cobbold L.C., Jopling C.L., Cooper R.E., Wilson L.A., Stoneley M., Coldwell M.J., Poncet D., Shen Y.C., Morley S.J., Bushell M., Willis A.E. Canonical initiation factor requirements of the Myc family of internal ribosome entry segments. Mol. Cell. Biol. 2009, 29:1565-1574.
22. Spriggs K.A., Bushell M., Mitchell S.A., Willis A.E. Internal ribosome entry segment-mediated translation during apoptosis: the role of IRES-trans-acting factors. Cell Death Differ. 2005, 12:585-591.
23. Fitzgerald K.D., Semler B.L. Bridging IRES elements in mRNAs to the eukaryotic translation apparatus. Biochim. Biophys. Acta 2009, 1789:518-528.
24. Bell J.L., Wachter K., Muhleck B., Pazaitis N., Kohn M., Lederer M., Huttelmaier S. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?. Cell. Mol. Life Sci. 2012, 70:2657-2675.
25. Nielsen J., Christiansen J., Lykke-Andersen J., Johnsen A.H., Wewer U.M., Nielsen F.C. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol. Cell. Biol. 1999, 19:1262-1270.
26. Faye M.D., Beug S.T., Graber T.E., Earl N., Xiang X., Wild B., Langlois S., Michaud J., Cowan K.N., Korneluk R.G., Holcik M. IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1. Oncogene 2014, [Epub ahead of print]. 10.1038/onc.2014.90.
27. Stohr N., Kohn M., Lederer M., Glass M., Reinke C., Singer R.H., Huttelmaier S. IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling. Genes Dev. 2012, 26:176-189.
28. Weidensdorfer D., Stohr N., Baude A., Lederer M., Kohn M., Schierhorn A., Buchmeier S., Wahle E., Huttelmaier S. Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic RNPs. RNA 2009, 15:104-115.
29. Sparanese D., Lee C.H. CRD-BP shields c-myc and MDR-1 RNA from endonucleolytic attack by a mammalian endoribonuclease. Nucleic Acids Res. 2007, 35:1209-1221.
30. Vikesaa J., Hansen T.V., Jonson L., Borup R., Wewer U.M., Christiansen J., Nielsen F.C. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J. 2006, 25:1456-1468.
31. Noubissi F.K., Goswami S., Sanek N.A., Kawakami K., Minamoto T., Moser A., Grinblat Y., Spiegelman V.S. Wnt signaling stimulates transcriptional outcome of the Hedgehog pathway by stabilizing GLI1 mRNA. Cancer Res. 2009, 69:8572-8578.
32. Gu W., Wells A.L., Pan F., Singer R.H. Feedback regulation between zipcode binding protein 1 and beta-catenin mRNAs in breast cancer cells. Mol. Cell. Biol. 2008, 28:4963-4974.
33. Hansen T.V., Hammer N.A., Nielsen J., Madsen M., Dalbaeck C., Wewer U.M., Christiansen J., Nielsen F.C. Dwarfism and impaired gut development in insulin-like growth factor II mRNA-binding protein 1-deficient mice. Mol. Cell. Biol. 2004, 24:4448-4464.
34. Dimitriadis E., Trangas T., Milatos S., Foukas P.G., Gioulbasanis I., Courtis N., Nielsen F.C., Pandis N., Dafni U., Bardi G., Ioannidis P. Expression of oncofetal RNA-binding protein CRD-BP/IMP1 predicts clinical outcome in colon cancer. Int. J. Cancer 2007, 121:486-494.
35. Dai N., Rapley J., Angel M., Yanik M.F., Blower M.D., Avruch J. mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal ribosomal entry. Genes Dev. 2011, 25:1159-1172.
36. Dai N., Christiansen J., Nielsen F.C., Avruch J. mTOR complex 2 phosphorylates IMP1 cotranslationally to promote IGF2 production and the proliferation of mouse embryonic fibroblasts. Genes Dev. 2013, 27:301-312.
37. Hamilton K.E., Noubissi F.K., Katti P.S., Hahn C.M., Davey S.R., Lundsmith E.T., Klein-Szanto A.J., Rhim A.D., Spiegelman V.S., Rustgi A.K. IMP1 promotes tumor growth, dissemination and a tumor-initiating cell phenotype in colorectal cancer cell xenografts. Carcinogenesis 2013, 34:2647-2654.
38. Gutschner T., Hammerle M., Pazaitis N., Bley N., Fiskin E., Uckelmann H., Heim A., Grobeta M., Hofmann N., Geffers R., Skawran B., Longerich T., Breuhahn K., Schirmacher P., Muhleck B., Huttelmaier S., Diederichs S. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma. Hepatology 2014, 59:1900-1911.
39. Lemm I., Ross J. Regulation of c-myc mRNA decay by translational pausing in a coding region instability determinant. Mol. Cell. Biol. 2002, 22:3959-3969.
40. Kobel M., Weidensdorfer D., Reinke C., Lederer M., Schmitt W.D., Zeng K., Thomssen C., Hauptmann S., Huttelmaier S. Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma. Oncogene 2007, 26:7584-7589.
41. Ioannidis P., Mahaira L.G., Perez S.A., Gritzapis A.D., Sotiropoulou P.A., Kavalakis G.J., Antsaklis A.I., Baxevanis C.N., Papamichail M. CRD-BP/IMP1 expression characterizes cord blood CD34+ stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cells. J. Biol. Chem. 2005, 280:20086-20093.
42. Mongroo P.S., Noubissi F.K., Cuatrecasas M., Kalabis J., King C.E., Johnstone C.N., Bowser M.J., Castells A., Spiegelman V.S., Rustgi A.K. IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2. Cancer Res. 2011, 71:2172-2182.
43. Stoneley M., Paulin F.E., Le Quesne J.P., Chappell S.A., Willis A.E. C-Myc 5' untranslated region contains an internal ribosome entry segment. Oncogene 1998, 16:423-428.
44. Chappell S.A., LeQuesne J.P., Paulin F.E., deSchoolmeester M.L., Stoneley M., Soutar R.L., Ralston S.H., Helfrich M.H., Willis A.E. A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: A novel mechanism of oncogene de-regulation. Oncogene 2000, 19:4437-4440.
45. Cobbold L.C., Wilson L.A., Sawicka K., King H.A., Kondrashov A.V., Spriggs K.A., Bushell M., Willis A.E. Upregulated c-myc expression in multiple myeloma by internal ribosome entry results from increased interactions with and expression of PTB-1 and YB-1. Oncogene 2010, 29:2884-2891.
46. Graber T.E., Baird S.D., Kao P.N., Mathews M.B., Holcik M. NF45 functions as an IRES trans-acting factor that is required for translation of cIAP1 during the unfolded protein response. Cell Death Differ. 2010, 17:719-729.
47. Gyrd-Hansen M., Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat. Rev. Cancer 2010, 10:561-574.
48. Beug S.T., Cheung H.H., LaCasse E.C., Korneluk R.G. Modulation of immune signalling by inhibitors of apoptosis. Trends Immunol. 2012, 33:535-545.
49. Petak I., Douglas L., Tillman D.M., Vernes R., Houghton J.A. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin. Cancer Res. 2000, 6:4119-4127.
50. Varfolomeev E., Blankenship J.W., Wayson S.M., Fedorova A.V., Kayagaki N., Garg P., Zobel K., Dynek J.N., Elliott L.O., Wallweber H.J., Flygare J.A., Fairbrother W.J., Deshayes K., Dixit V.M., Vucic D. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007, 131:669-681.
51. Craig E.A., Spiegelman V.S. Inhibition of coding region determinant binding protein sensitizes melanoma cells to chemotherapeutic agents. Pigment Cell Melanoma Res. 2012, 25:83-87.
52. Boyerinas B., Park S.M., Murmann A.E., Gwin K., Montag A.G., Zillhardt M., Hua Y.J., Lengyel E., Peter M.E. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int. J. Cancer 2012, 130:1787-1797.
53. Huttelmaier S., Zenklusen D., Lederer M., Dictenberg J., Lorenz M., Meng X., Bassell G.J., Condeelis J., Singer R.H. Spatial regulation of beta-actin translation by Src-dependent phosphorylation of ZBP1. Nature 2005, 438:512-515.
54. Ross A.F., Oleynikov Y., Kislauskis E.H., Taneja K.L., Singer R.H. Characterization of a beta-actin mRNA zipcode-binding protein. Mol. Cell. Biol. 1997, 17:2158-2165.
55. Tessier C.R., Doyle G.A., Clark B.A., Pitot H.C., Ross J. Mammary tumor induction in transgenic mice expressing an RNA-binding protein. Cancer Res. 2004, 64:209-214.
56. Wang W., Goswami S., Lapidus K., Wells A.L., Wyckoff J.B., Sahai E., Singer R.H., Segall J.E., Condeelis J.S. Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res. 2004, 64:8585-8594.
57. Gu W., Pan F., Singer R.H. Blocking beta-catenin binding to the ZBP1 promoter represses ZBP1 expression, leading to increased proliferation and migration of metastatic breast-cancer cells. J. Cell Sci. 2009, 122:1895-1905.
58. Gu W., Katz Z., Wu B., Park H.Y., Li D., Lin S., Wells A.L., Singer R.H. Regulation of local expression of cell adhesion and motility-related mRNAs in breast cancer cells by IMP1/ZBP1. J. Cell Sci. 2012, 125:81-91.
59. Stohr N., Huttelmaier S. IGF2BP1: a post-transcriptional "driver" of tumor cell migration. Cell Adhes. Migr. 2012, 6:312-318.
60. During R.L., Gibson B.G., Li W., Bishai E.A., Sidhu G.S., Landry J., Southwick F.S. Anthrax lethal toxin paralyzes actin-based motility by blocking Hsp27 phosphorylation. EMBO J. 2007, 26:2240-2250.
61. Zirkel A., Lederer M., Stohr N., Pazaitis N., Huttelmaier S. IGF2BP1 promotes mesenchymal cell properties and migration of tumor-derived cells by enhancing the expression of LEF1 and SNAI2 (SLUG). Nucleic Acids Res. 2013, 41:6618-6636.
62. Manieri N.A., Drylewicz M.R., Miyoshi H., Stappenbeck T.S. Igf2bp1 is required for full induction of Ptgs2 mRNA in colonic mesenchymal stem cells in mice. Gastroenterology 2012, 143:110-121. (e110).
63. Kao P.N., Chen L., Brock G., Ng J., Kenny J., Smith A.J., Corthesy B. Cloning and expression of cyclosporin A- and FK506-sensitive nuclear factor of activated T-cells: NF45 and NF90. J. Biol. Chem. 1994, 269:20691-20699.
64. Guan D., Altan-Bonnet N., Parrott A.M., Arrigo C.J., Li Q., Khaleduzzaman M., Li H., Lee C.G., Pe'ery T., Mathews M.B. Nuclear factor 45 (NF45) is a regulatory subunit of complexes with NF90/110 involved in mitotic control. Mol. Cell. Biol. 2008, 28:4629-4641.
65. Masuda K., Kuwano Y., Nishida K., Rokutan K., Imoto I. NF90 in posttranscriptional gene regulation and microRNA biogenesis. Int. J. Mol. Sci. 2013, 14:17111-17121.
66. Kuwano Y., Pullmann R., Marasa B.S., Abdelmohsen K., Lee E.K., Yang X., Martindale J.L., Zhan M., Gorospe M. NF90 selectively represses the translation of target mRNAs bearing an AU-rich signature motif. Nucleic Acids Res. 2010, 38:225-238.
67. Faye M.D., Graber T.E., Liu P., Thakor N., Baird S.D., Durie D., Holcik M. Nucleotide composition of cellular internal ribosome entry sites defines dependence on NF45 and predicts a posttranscriptional mitotic regulon. Mol. Cell. Biol. 2013, 33:307-318.
68. Vumbaca F., Phoenix K.N., Rodriguez-Pinto D., Han D.K., Claffey K.P. Double-stranded RNA-binding protein regulates vascular endothelial growth factor mRNA stability, translation, and breast cancer angiogenesis. Mol. Cell. Biol. 2008, 28:772-783.
69. Urcuqui-Inchima S., Castano M.E., Hernandez-Verdun D., St-Laurent G., Kumar A. Nuclear Factor 90, a cellular dsRNA binding protein inhibits the HIV Rev-export function. Retrovirology 2006, 3:83.
70. Sakamoto S., Aoki K., Higuchi T., Todaka H., Morisawa K., Tamaki N., Hatano E., Fukushima A., Taniguchi T., Agata Y. The NF90-NF45 complex functions as a negative regulator in the microRNA processing pathway. Mol. Cell. Biol. 2009, 29:3754-3769.
71. Haselmann V., Kurz A., Bertsch U., Hubner S., Olempska-Muller M., Fritsch J., Hasler R., Pickl A., Fritsche H., Annewanter F., Engler C., Fleig B., Bernt A., Roder C., Schmidt H., Gelhaus C., Hauser C., Egberts J.H., Heneweer C., Rohde A.M., Boger C., Knippschild U., Rocken C., Adam D., Walczak H., Schutze S., Janssen O., Wulczyn F.G., Wajant H., Kalthoff H., Trauzold A. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells. Gastroenterology 2014, 146:278-290.
72. Merrill M.K., Gromeier M. The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site. J. Virol. 2006, 80:6936-6942.
73. Gomila R.C., Martin G.W., Gehrke L. NF90 binds the dengue virus RNA 3' terminus and is a positive regulator of dengue virus replication. PLoS One 2011, 6:e16687.
74. Lee Y.Y., McKinney K.Q., Ghosh S., Iannitti D.A., Martinie J.B., Caballes F.R., Russo M.W., Ahrens W.A., Lundgren D.H., Han D.K., Bonkovsky H.L., Hwang S.I. Subcellular tissue proteomics of hepatocellular carcinoma for molecular signature discovery. J. Proteome Res. 2011, 10:5070-5083.
75. Haskins W.E., Eedala S., Jadhav Y.L., Labhan M.S., Pericherla V.C., Perlman E.J. Insights on neoplastic stem cells from gel-based proteomics of childhood germ cell tumors. Pediatr. Blood Cancer 2012, 58:722-728.
76. Chung F.H., Lee H.H., Lee H.C. ToP: a trend-of-disease-progression procedure works well for identifying cancer genes from multi-state cohort gene expression data for human colorectal cancer. PLoS One 2013, 8:e65683.
77. Guo N.L., Tosun K., Horn K. Impact and interactions between smoking and traditional prognostic factors in lung cancer progression. Lung Cancer 2009, 66:386-392.
78. Guo Y., Fu P., Zhu H., Reed E., Remick S.C., Petros W., Mueller M.D., Yu J.J. Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer. Oncol. Rep. 2012, 27:286-292.
79. Warnakulasuriyarachchi D., Ungureanu N.H., Holcik M. The translation of an antiapoptotic protein HIAP2 is regulated by an upstream open reading frame. Cell Death Differ. 2003, 10:899-904.
80. Warnakulasuriyarachchi D., Cerquozzi S., Cheung H.H., Holcik M. Translational induction of the inhibitor of apoptosis protein HIAP2 during endoplasmic reticulum stress attenuates cell death and is mediated via an inducible internal ribosome entry site element. J. Biol. Chem. 2004, 279:17148-17157.
81. Tominaga-Yamanaka K., Abdelmohsen K., Martindale J.L., Yang X., Taub D.D., Gorospe M. NF90 coordinately represses the senescence-associated secretory phenotype. Aging 2012, 4:695-708.
82. Shamanna R.A., Hoque M., Lewis-Antes A., Azzam E.I., Lagunoff D., Pe'ery T., Mathews M.B. The NF90/NF45 complex participates in DNA break repair via nonhomologous end joining. Mol. Cell. Biol. 2011, 31:4832-4843.
83. Mita A.C., Mita M.M., Nawrocki S.T., Giles F.J. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res. 2008, 14:5000-5005.
84. Ting N.S., Kao P.N., Chan D.W., Lintott L.G., Lees-Miller S.P. DNA-dependent protein kinase interacts with antigen receptor response element binding proteins NF90 and NF45. J. Biol. Chem. 1998, 273:2136-2145.
85. Shamanna R.A., Hoque M., Pe'ery T., Mathews M.B. Induction of p53, p21 and apoptosis by silencing the NF90/NF45 complex in human papilloma virus-transformed cervical carcinoma cells. Oncogene 2013, 32:5176-5185.
86. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-1136.
87. Huibregtse J.M., Scheffner M., Howley P.M. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 1991, 10:4129-4135.
88. Gregory R.I., Yan K.P., Amuthan G., Chendrimada T., Doratotaj B., Cooch N., Shiekhattar R. The Microprocessor complex mediates the genesis of microRNAs. Nature 2004, 432:235-240.
89. Hu Q., Lu Y.Y., Noh H., Hong S., Dong Z., Ding H.F., Su S.B., Huang S. Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression. Oncogene 2013, 32:3933-3943.
90. Shibahara K., Asano M., Ishida Y., Aoki T., Koike T., Honjo T. Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Gene 1995, 166:297-301.
91. Lankat-Buttgereit B., Goke R. The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biol. Cell 2009, 101:309-317.
92. Cmarik J.L., Min H., Hegamyer G., Zhan S., Kulesz-Martin M., Yoshinaga H., Matsuhashi S., Colburn N.H. Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:14037-14042.
93. Buscaglia L.E., Li Y. Apoptosis and the target genes of microRNA-21. Chin. J. Cancer 2011, 30:371-380.
94. Huang Y., Yang Y.B., Zhang X.H., Yu X.L., Wang Z.B., Cheng X.C. MicroRNA-21 gene and cancer. Med. Oncol. 2013, 30:376.
95. Lu Z., Liu M., Stribinskis V., Klinge C.M., Ramos K.S., Colburn N.H., Li Y. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008, 27:4373-4379.
96. Asangani I.A., Rasheed S.A., Nikolova D.A., Leupold J.H., Colburn N.H., Post S., Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27:2128-2136.
97. Frankel L.B., Christoffersen N.R., Jacobsen A., Lindow M., Krogh A., Lund A.H. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem. 2008, 283:1026-1033.
98. Dorrello N.V., Peschiaroli A., Guardavaccaro D., Colburn N.H., Sherman N.E., Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006, 314:467-471.
99. Schmid T., Jansen A.P., Baker A.R., Hegamyer G., Hagan J.P., Colburn N.H. Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion. Cancer Res. 2008, 68:1254-1260.
100. Yang H.S., Jansen A.P., Komar A.A., Zheng X., Merrick W.C., Costes S., Lockett S.J., Sonenberg N., Colburn N.H. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol. Cell. Biol. 2003, 23:26-37.
101. Goke A., Goke R., Knolle A., Trusheim H., Schmidt H., Wilmen A., Carmody R., Goke B., Chen Y.H. DUG is a novel homologue of translation initiation factor 4G that binds eIF4A. Biochem. Biophys. Res. Commun. 2002, 297:78-82.
102. Liwak U., Thakor N., Jordan L.E., Roy R., Lewis S.M., Pardo O.E., Seckl M., Holcik M. Tumor suppressor PDCD4 represses internal ribosome entry site-mediated translation of antiapoptotic proteins and is regulated by S6 kinase 2. Mol. Cell. Biol. 2012, 32:1818-1829.
103. LaRonde-LeBlanc N., Santhanam A.N., Baker A.R., Wlodawer A., Colburn N.H. Structural basis for inhibition of translation by the tumor suppressor Pdcd4. Mol. Cell. Biol. 2007, 27:147-156.
104. Suzuki C., Garces R.G., Edmonds K.A., Hiller S., Hyberts S.G., Marintchev A., Wagner G. PDCD4 inhibits translation initiation by binding to eIF4A using both its MA3 domains. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3274-3279.
105. Yang H.S., Cho M.H., Zakowicz H., Hegamyer G., Sonenberg N., Colburn N.H. A Novel Function of the MA-3 Domains in Transformation and Translation Suppressor Pdcd4 Is Essential for Its Binding to Eukaryotic Translation Initiation Factor 4A. Mol. Cell. Biol. 2004, 24:3894-3906.
106. Wedeken L., Singh P., Klempnauer K.H. Tumor suppressor protein Pdcd4 inhibits translation of p53 mRNA. J. Biol. Chem. 2011, 286:42855-42862.
107. Bitomsky N., Wethkamp N., Marikkannu R., Klempnauer K.H. siRNA-mediated knockdown of Pdcd4 expression causes upregulation of p21(Waf1/Cip1) expression. Oncogene 2008, 27:4820-4829.
108. Singh P., Wedeken L., Waters L.C., Carr M.D., Klempnauer K.H. Pdcd4 directly binds the coding region of c-myb mRNA and suppresses its translation. Oncogene 2011, 30:4864-4873.
109. Biyanee A., Ohnheiser J., Singh P., Klempnauer K.H. A novel mechanism for the control of translation of specific mRNAs by tumor suppressor protein Pdcd4: inhibition of translation elongation. Oncogene 2014, [Epub ahead of print]. 10.1038/onc.2014.83.
110. Pardo O.E., Wellbrock C., Khanzada U.K., Aubert M., Arozarena I., Davidson S., Bowen F., Parker P.J., Filonenko V.V., Gout I.T., Sebire N., Marais R., Downward J., Seckl M.J. FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J. 2006, 25:3078-3088.
111. Liwak U., Jordan L.E., Von-Holt S.D., Singh P., Hanson J.E., Lorimer I.A., Roncaroli F., Holcik M. Loss of PDCD4 contributes to enhanced chemoresistance in Glioblastoma multiforme through de-repression of Bcl-xL translation. Oncotarget 2013, 4:1365-1372.
112. Yang H.S., Matthews C.P., Clair T., Wang Q., Baker A.R., Li C.C., Tan T.H., Colburn N.H. Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion. Mol. Cell. Biol. 2006, 26:1297-1306.
113. Nieves-Alicea R., Colburn N.H., Simeone A.M., Tari A.M. Programmed cell death 4 inhibits breast cancer cell invasion by increasing tissue inhibitor of metalloproteinases-2 expression. Breast Cancer Res. Treat. 2009, 114:203-209.
114. Wei N., Liu S.S., Chan K.K., Ngan H.Y. Tumour suppressive function and modulation of programmed cell death 4 (PDCD4) in ovarian cancer. PLoS One 2012, 7:e30311.
115. Wang Q., Sun Z.X., Allgayer H., Yang H.S. Downregulation of E-cadherin is an essential event in activating beta-catenin/Tcf-dependent transcription and expression of its target genes in Pdcd4 knockdown cells. Oncogene 2010, 29:128-138.
116. Wang Q., Sun Z., Yang H.S. Downregulation of tumor suppressor Pdcd4 promotes invasion and activates both beta-catenin/Tcf and AP-1-dependent transcription in colon carcinoma cells. Oncogene 2008, 27:1527-1535.
117. Cano A., Perez-Moreno M.A., Rodrigo I., Locascio A., Blanco M.J., del Barrio M.G., Portillo F., Nieto M.A. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2000, 2:76-83.
118. Wang Q., Zhu J., Zhang Y., Sun Z., Guo X., Wang X., Lee E., Bakthavatchalu V., Yang Q., Yang H.S. Down-regulation of programmed cell death 4 leads to epithelial to mesenchymal transition and promotes metastasis in mice. Eur. J. Cancer 2013, 49:1761-1770.
119. Evdokimova V., Tognon C., Ng T., Ruzanov P., Melnyk N., Fink D., Sorokin A., Ovchinnikov L.P., Davicioni E., Triche T.J., Sorensen P.H. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009, 15:402-415.
120. Gillis L.D., Lewis S.M. Decreased eIF3e/Int6 expression causes epithelial-to-mesenchymal transition in breast epithelial cells. Oncogene 2013, 32:3598-3605.
121. Yamanaka S., Poksay K.S., Arnold K.S., Innerarity T.L. A novel translational repressor mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA-editing enzyme. Genes Dev. 1997, 11:321-333.
122. Lee S.H., McCormick F. p97/DAP5 is a ribosome-associated factor that facilitates protein synthesis and cell proliferation by modulating the synthesis of cell cycle proteins. EMBO J. 2006, 25:4008-4019.
123. Morley S.J., Coldwell M.J., Clemens M.J. Initiation factor modifications in the preapoptotic phase. Cell Death Differ. 2005, 12:571-584.
124. Hundsdoerfer P., Thoma C., Hentze M.W. Eukaryotic translation initiation factor 4GI and p97 promote cellular internal ribosome entry sequence-driven translation. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:13421-13426. (Epub 12005 Sep 13427).
125. Lewis S.M., Cerquozzi S., Graber T.E., Ungureanu N.H., Andrews M., Holcik M. The eIF4G homolog DAP5/p97 supports the translation of select mRNAs during endoplasmic reticulum stress. Nucleic Acids Res. 2008, 36:168-178.
126. Lee S.H., McCormick F. p97/DAP5 is a ribosome-associated factor that facilitates protein synthesis and cell proliferation by modulating the synthesis of cell cycle proteins. EMBO J. 2006, 25:4008-4019.
127. Yamanaka S., Zhang X.Y., Maeda M., Miura K., Wang S., Farese R.V., Iwao H., Innerarity T.L. Essential role of NAT1/p97/DAP5 in embryonic differentiation and the retinoic acid pathway. EMBO J. 2000, 19:5533-5541.
128. Nevins T.A., Harder Z.M., Korneluk R.G., Holcik M. Distinct regulation of internal ribosome entry site-mediated translation following cellular stress is mediated by apoptotic fragments of eIF4G translation initiation factor family members eIF4GI and p97/DAP5/NAT1. J. Biol. Chem. 2003, 278:3572-3579.
129. Henis-Korenblit S., Shani G., Sines T., Marash L., Shohat G., Kimchi A. The caspase-cleaved DAP5 protein supports internal ribosome entry site-mediated translation of death proteins. PNAS 2002, 99:5400-5405.
130. Marash L., Liberman N., Henis-Korenblit S., Sivan G., Reem E., Elroy-Stein O., Kimchi A. DAP5 promotes cap-independent translation of Bcl-2 and CDK1 to facilitate cell survival during mitosis. Mol. Cell 2008, 30:447-459. (Epub 2008 May 2001).
131. Liberman N., Marash L., Kimchi A. The translation initiation factor DAP5 is a regulator of cell survival during mitosis. Cell Cycle 2009, 8:204-209.
132. Yang D.Q., Halaby M.J., Zhang Y. The identification of an internal ribosomal entry site in the 5'-untranslated region of p53 mRNA provides a novel mechanism for the regulation of its translation following DNA damage. Oncogene 2006, 25:4613-4619.
133. Ray P.S., Grover R., Das S. Two internal ribosome entry sites mediate the translation of p53 isoforms. EMBO Rep. 2006, 7:404-410.
134. Weingarten-Gabbay S., Khan D., Liberman N., Yoffe Y., Bialik S., Das S., Oren M., Kimchi A. The translation initiation factor DAP5 promotes IRES-driven translation of p53 mRNA. Oncogene 2014, 33:611-618.
135. Courtois S., Verhaegh G., North S., Luciani M.G., Lassus P., Hibner U., Oren M., Hainaut P. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 2002, 21:6722-6728.
136. Candeias M.M., Powell D.J., Roubalova E., Apcher S., Bourougaa K., Vojtesek B., Bruzzoni-Giovanelli H., Fahraeus R. Expression of p53 and p53/47 are controlled by alternative mechanisms of messenger RNA translation initiation. Oncogene 2006, 25:6936-6947.
137. Lewis S.M., Holcik M. For IRES trans-acting factors, it is all about location. Oncogene 2008, 27:1033-1035.
138. Pan X., Wang Z.X., Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol. Ther. 2010, 10:1224-1232.
139. Didiot M.C., Hewett J., Varin T., Freuler F., Selinger D., Nick H., Reinhardt J., Buckler A., Myer V., Schuffenhauer A., Guy C.T., Parker C.N. Identification of cardiac glycoside molecules as inhibitors of c-Myc IRES-mediated translation. J. Biomol. Screen. 2013, 18:407-419.